Connect Biopharma Holdings Limited
NASDAQ:CNTBBiotechnology
-$0.09 today
- Market cap
- $50.52M
- Beta
- -0.21
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.50
Volume 2.50M
Average 0.30M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Connect Biopharma Holdings Limited
NASDAQ:CNTB
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +300.6% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +300.6% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Shattuck Labs, Inc. NASDAQ:STTK | $558.02M | $5.56 | Not rated | -10.9 | +132.14% |
Ovid Therapeutics Inc. NASDAQ:OVID | $496.06M | $2.54 | Not rated | -7.1 | +82.81% |
InflaRx N.V. NASDAQ:IFRX | $244.63M | $1.66 | Not rated | -2.7 | -13.49% |
Artiva Biotherapeutics, Inc. NASDAQ:ARTV | $204.85M | $4.19 | Not rated | -2.7 | +12.98% |
Sutro Biopharma, Inc. NASDAQ:STRO | $150.89M | $9.10 | Not rated | -0.0 | -4.18% |
ImageneBio Inc NASDAQ:IMA | $46.54M | $4.10 | Not rated | -1.5 | -37.11% |
Kalaris Therapeutics Inc NASDAQ:KLRS | $44.34M | $2.03 | Not rated | -2.5 | -65.57% |
Context Therapeutics Inc. NASDAQ:CNTX | $17.37M | $0.19 | Not rated | -1.5 | -40.77% |
Continue the stock analysis
Jump to another research area for this company.